Literature DB >> 9384238

Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.

A B Fawzi1, H Zhang, B Weig, B Hawes, M P Graziano.   

Abstract

Opioid receptor-like 1 (ORL1) receptor, a member of the superfamily of G-protein-coupled receptors has significant primary sequence homology to the mu-, delta- and kappa-opioid receptors. The ORL1 receptor is selectively activated by the recently discovered peptide nociceptin. To probe the functional homology amongst these receptors, a Chinese hamster ovary (CHO) cell line expressing the human ORL1 receptor has been characterized. Nociceptin inhibited forskolin-stimulated increases in intracellular cAMP with an IC50 of 70 pM. Stimulation by nociceptin caused a 2-fold increase in the rate of [35S]GTPgammaS binding to membranes derived from CHO cells expressing the ORL1 receptor. Following incubation with nociceptin mitogen-activated protein kinase activity was increased by 2-fold in cells expressing the ORL1 receptor. In non-transfected CHO cells, nociceptin had no effect on cAMP accumulation, the rate of [35S]GTPgammaS binding or mitogen-activated protein kinase activity. Human ORL1 receptors expressed in CHO cells selectively bound [125I][Tyr14]nociceptin with a Kd of 2.1 pM and a Bmax of 2.6 pmol/mg protein. Similar to opioid receptors, nociceptin binding to the ORL1 receptor was altered by Na+, GTPgammaS and dithiothreitol. Na+ increased the Kd of nociceptin binding to the ORL1 receptor. GTPgammaS decreased the apparent Bmax of [125I][Tyr14]nociceptin binding but had no effect on the Kd of the remaining sites. Pretreatment with dithiothreitol inhibited nociceptin binding to the ORL1 receptor. Nociceptin binding was insensitive to low nanomolar concentrations of opioid receptor-selective agonists and antagonists. However, high micromolar levels of opioid receptor-selective agents inhibited the binding. Morphine, naloxone, naltrindole, nor-Binaltorphimine and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) inhibited nociceptin binding to ORL1 receptor with Ki values of 36, 24, 0.4, 8 and 28 microM, respectively. These results imply that ORL1 is a G-protein-coupled receptor with functional as well as structural homology to opioid receptors. In addition, opioid receptor ligands may serve as starting templates for the development of ORL1 specific ligands.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9384238     DOI: 10.1016/s0014-2999(97)01227-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

2.  Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors.

Authors:  H Okawa; B Nicol; R Bigoni; R A Hirst; G Calo; R Guerrini; D J Rowbotham; D Smart; A T McKnight; D G Lambert
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors.

Authors:  R L McLeod; L E Parra; J C Mutter; C H Erickson; G J Carey; D B Tulshian; A B Fawzi; A Smith-Torhan; R W Egan; F M Cuss; J A Hey
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

4.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

5.  Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.

Authors:  Robbie L McLeod; Deen B Tulshian; Donald C Bolser; Geoffrey B Varty; Marco Baptista; Xiomara Fernandez; Leonard E Parra; Jennifer C Zimmer; Christine H Erickson; Ginny D Ho; Yanlin Jia; Fay W Ng; Walter Korfmacher; Xiaoying Xu; John Veals; April Smith-Torhan; Samuel Wainhaus; Ahmad B Fawzi; Theodore M Austin; Margaret van Heek; John A Hey
Journal:  Eur J Pharmacol       Date:  2009-12-16       Impact factor: 4.432

Review 6.  The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction.

Authors:  Kabirullah Lutfy; Nurulain T Zaveri
Journal:  Prog Mol Biol Transl Sci       Date:  2015-12-23       Impact factor: 3.622

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.